论文部分内容阅读
目的建立杭州地区健康成年人血小板的聚集功能的参考范围。方法以不同终浓度的二磷酸腺苷(ADP)(2μmol/L,1μmol/L)和肾上腺素(EP)(5.56μmol/L,2.78μmol/L)为诱导剂,采用光学比浊法分别检测241名健康志愿者的血小板的聚集率,求出1 min时及最大聚集率值。另选32例心肌梗死患者进行血小板聚集功能的检测。结果以终浓度2μmol/L,1μmol/L ADP为诱导剂时,正常人群血小板的1 min聚集率分别为(43.35±9.05)%,(37.04±5.32)%;最大聚集率分别为(60.83±4.29)%,(55.91±6.13)%。以终浓度5.56μmol/L,2.78μmol/L EP为诱导剂时,正常人群血小板的1 min聚集率分别为(26.74±9.82)%,(22.26±9.41)%;最大聚集率分别为(58.12±8.50)%,(45.65±9.78)%。以ADP为诱导剂时,心肌梗死患者组的1 min及最大聚集率均显著高于正常对照组;以EP为诱导剂时,心肌梗死患者组的最大聚集率明显高于正常对照组。结论本实验建立了杭州地区健康成年人群血小板聚集功能的参考范围,可为临床高凝状态的监测以及抗凝药物疗效的观察提供参考依据。
Objective To establish a reference range of platelet aggregation in healthy adults in Hangzhou. Methods The phototurbidimetric method was used to detect the effects of different concentrations of ADP (2μmol / L, 1μmol / L) and epinephrine (5.56μmol / L, 2.78μmol / L) In 241 healthy volunteers, the platelet aggregation rate was calculated and the maximum aggregation rate was calculated at 1 min. Another 32 patients with myocardial infarction platelet aggregation test. Results The 1-min platelet aggregation rate in normal population was (43.35 ± 9.05)% and (37.04 ± 5.32)%, respectively, at the concentrations of 2μmol / L and 1μmol / L ADP. The maximum aggregation rates were (60.83 ± 4.29 )%, (55.91 ± 6.13)%. When the final concentration of 5.56μmol / L and 2.78μmol / L EP were used as inducer, the 1-minute platelet aggregation rate in normal population was (26.74 ± 9.82)% and (22.26 ± 9.41)% respectively, and the maximum aggregation rate was (58.12 ± 8.50)%, (45.65 ± 9.78)%. When ADP was used as an inducer, the 1-min and maximal aggregation rate of myocardial infarction patients were significantly higher than that of normal control group. When EP was used as an inducer, the maximal aggregation rate of myocardial infarction patients was significantly higher than that of normal control group. Conclusion This study established a reference range of platelet aggregation in healthy adult population in Hangzhou, which can provide reference for the monitoring of clinical hypercoagulable state and the observation of anticoagulant efficacy.